Wikipedia:Articles for deletion/Lipactin


 * The following discussion is an archived debate of the proposed deletion of the article below. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review).  No further edits should be made to this page.

The result was   delete.   A rbitrarily 0   ( talk ) 14:12, 17 February 2010 (UTC)

Lipactin

 * – ( View AfD View log  •  )

Non-notable medicament. Only one study ever performed. No secondary sources talking about its importance, etc. No sources to write an article that goes beyond what Novartis claims for their product. Enric Naval (talk) 17:59, 10 February 2010 (UTC)
 * Note: This debate has been included in the list of Medicine-related deletion discussions.  —Enric Naval (talk) 18:04, 10 February 2010 (UTC)


 * Delete, zero PubMed hits, only Google Scholar hits are unrelated CMAJ articles that happen to contain an advertisement for this product. Tim Vickers (talk) 18:50, 10 February 2010 (UTC)
 * Delete per TimVickers. PanydThe muffin is not subtle 19:28, 10 February 2010 (UTC)
 * Redirect (without deletion) to heparin. I've copied the reference to that page. Though P Sharma (Pharmacy practice 2006, 22(3):22-24) doesn't seem to see it a real trial, so maybe my edit should be undone. Narayanese (talk) 21:04, 10 February 2010 (UTC)
 * I thought about that, but I don't think you can really redirect an article about a product with two active ingredients to an article on one of those ingredients. Tim Vickers (talk) 21:14, 10 February 2010 (UTC)
 * Delete True, zinc sulphate has effects on its own. Given the safety concern of Bourne and others it's a bad idea for wikipedia to cover a drug that hasn't been tested for negative effects. The one thing an external review of german wikipedia's drug coverage complained about was the lack of listing of adverse effects I remember. Narayanese (talk) 21:33, 10 February 2010 (UTC)
 * The above discussion is preserved as an archive of the debate. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.